News from nektar therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 09, 2023, 16:15 ET Nektar Therapeutics Reports First Quarter 2023 Financial Results

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2023. Cash and investments in marketable...

Apr 27, 2023, 08:30 ET Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development

Nektar Therapeutics (Nasdaq: NKTR) today announced that it will be regaining the full rights to REZPEG from Eli Lilly and Company. As announced in a...

Apr 17, 2023, 17:00 ET Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan

-- Pipeline focus will prioritize programs in immunology, including REZPEG and several immunology research programs -- -- Development of NKTR-255 in...

Mar 11, 2023, 19:00 ET Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank

Nektar Therapeutics (Nasdaq: NKTR) today issued a statement confirming that it does not have any accounts at Silicon Valley Bank, and it does not...

Feb 28, 2023, 17:15 ET Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2022. Cash and...

Feb 23, 2023, 16:30 ET Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus

Nektar Therapeutics (Nasdaq: NKTR) today announced topline data from a Phase 2 randomized, double-blind, placebo-controlled study of...

Jan 04, 2023, 09:00 ET Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual J.P....

Dec 12, 2022, 10:05 ET Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

...

Dec 05, 2022, 08:00 ET Nektar Therapeutics to Host Investor & Analyst Event on December 12th

Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an investor and analyst event on Monday, December 12, 2022 at 7:30 a.m. CST....

Nov 10, 2022, 09:05 ET Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for Immunotherapy of...

Nov 09, 2022, 09:00 ET Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy

Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American...

Nov 03, 2022, 16:15 ET Nektar Therapeutics Reports Third Quarter 2022 Financial Results

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2022. Cash and investments in...

Oct 25, 2022, 18:00 ET Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2022 on Thursday, November 3, 2022, after the close of U....

Sep 07, 2022, 01:15 ET Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress

Nektar Therapeutics (Nasdaq: NKTR) today announced data presentations from two Phase 1b, proof-of-concept studies of rezpegaldesleukin (also known as ...

Aug 16, 2022, 08:30 ET Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma

Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American...

Aug 04, 2022, 16:15 ET Nektar Therapeutics Reports Second Quarter 2022 Financial Results

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2022. Cash and investments in marketable...

Jul 26, 2022, 18:00 ET Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2022 on Thursday, August 4, 2022, after the close of...

Jul 01, 2022, 06:30 ET Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer

Nektar Therapeutics (Nasdaq: NKTR) today announced the promotion of Jillian B. Thomsen to Senior Vice President (SVP) & Chief Financial Officer. Ms....

May 05, 2022, 16:15 ET Nektar Therapeutics Reports First Quarter 2022 Financial Results

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2022. Cash and investments in marketable...

Apr 25, 2022, 16:30 ET Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook

Nektar Therapeutics (Nasdaq: NKTR) today announced a new strategic plan focused on prioritizing key research and development efforts that will be...

Apr 23, 2022, 17:30 ET Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®

Nektar Therapeutics (Nasdaq: NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College today presented data from...

Apr 22, 2022, 08:30 ET Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan

Nektar Therapeutics (NASDAQ:NKTR) will host an analyst and investor conference call with Nektar executives on Monday, April 25, 2022, at 2:00 p.m....

Mar 14, 2022, 07:05 ET Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial

Nektar Therapeutics (NASDAQ:NKTR) will hold an analyst and investor conference call with Nektar management today, Monday, March 14, 2022, at 5:00 a.m....

Feb 28, 2022, 16:15 ET Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2021. Cash and...

Feb 17, 2022, 18:00 ET Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2021 on Monday, February 28, 2022, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2021 on Monday, February...